Tequin (gatifloxacin), an antiobiotic is that widely prescribed, may be linked to diabetes and other blood sugar conditions and disorders.
The New England Journal of Medicine will publish a report shortly that shows Tequin users had 17 times greater risk of developing serious diabetes and 4 times greater risk of being hospitalized with low blood sugar complications than patients using other antibiotics.
Last month, the Canadian study released linked Tequin to diabetes and other blood sugar disorders. Dr. David Juurlink of the Sunnybrook and Women's College Health Sciences Center in Toronto asked the health industry if it would be perhaps in consumers' best interests to pull the drug. Go here to read the NEJM article in summary form.
This year FDA added a warning to the Tequin label. What is significant however is the report that problems can arise from short term usage of the medication.
